布地奈德福莫特罗吸入粉雾剂治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征的效果分析

Effect of budesonide and formoterol fumarate powder for inhalation in the treatment of bronchial asthma-chronic obstructive pulmonary disease overlap syndrome

目的分析布地奈德福莫特罗吸入粉雾剂治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征的临床效果。方法70例支气管哮喘-慢性阻塞性肺疾病重叠综合征患者,采用随机数字表法分为对照组和观察组,每组35例。对照组患者给予噻托溴铵粉雾剂治疗,观察组采取布地奈德福莫特罗吸入粉雾剂治疗。比较两组症状消失时间、临床疗效、不良反应发生情况及治疗前后第1秒用力呼气容积、用力肺活量、呼出气一氧化氮水平。结果观察组哮喘症状消失时间(5.68±1.01)d、咳嗽消失时间(7.21±2.51)d及肺啰音消失时间(6.45±1.21)d均短于对照组的(7.56±2.21)、(9.21±3.18)、(9.21±2.91)d,差异具有统计学意义(P<0.05)。治疗后,两组第1秒用力呼气容积、用力肺活量、呼出气一氧化氮均较治疗前改善,且观察组第1秒用力呼气容积、用力肺活量、呼出气一氧化氮改善程度显著大于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为94.29%,高于对照组的74.29%,差异有统计学意义(P<0.05)。两组治疗过程中未发生不良反应。结论采用布地奈德福莫特罗吸入粉雾剂治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征,其临床效果确切,可有效改善患者的肺功能,加速各种症状消失,缩短治疗时间。

Objective To analyze the clinical effect of budesonide and formoterol fumarate powder for inhalation in the treatment of bronchial asthma-chronic obstructive pulmonary disease overlap syndrome.Methods A total of 70 patients with bronchial asthma-chronic obstructive pulmonary disease overlap syndrome were divided into control group and observation group according to random numerical table,with 35 cases in each group.The control group was treated with tiotropium bromide powder for inhalation,and the observation group was treated with budesonide and formoterol fumarate powder for inhalation.The symptom disappearance time,clinical efficacy,occurrence of adverse reactions,forced expiratory volume in the first second,forced vital capacity and exhaled nitric oxide levels before and after treatment were compared between the two groups.Results The disappearance time of asthma symptoms,cough disappearance and pulmonary rales in the observation group were(5.68±1.01),(7.21±2.51)d,(6.45±1.21)d respectively,which were shorter than(7.56±2.21),(9.21±3.18),(9.21±2.91)d of the control group,and the difference was statistically significant(P<0.05).After treatment,the forced expiratory volume in the first second,forced vital capacity and exhaled nitric oxide levels of the two groups were improve compared than those before treatment,and the observation group was better than the control group.All the difference was statistically significant(P<0.05).The total effective rate of the observation group was 94.29%,which was higher than 74.29%of the control group,and the difference was statistically significant(P<0.05).No adverse reactions occurred in the two groups during treatment.Conclusion Budesonide and formoterol fumarate powder for inhalation shows affirmative clinical effect in the treatment of bronchial asthma-chronic obstructive pulmonary disease overlap syndrome,which can effectively improve the lung function of patients,accelerate the disappearance of various symptoms and shorten the treatment time.